Drug Profile

T cell receptor-based T cell therapy - SPH Biotherapeutics (Shanghai)

Alternative Names: T cell receptor-engineered T cells - SPH Biotherapeutics (Shanghai); TP53 R248Q TCR-T cells - SPH Biotherapeutics

Latest Information Update: 17 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator SPH Biotherapeutics (Shanghai)
Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

27 Feb 2026 Preclinical trials in Cancer in China (Parenteral)
06 Dec 2025 Pharmacodynamics data from a preclinical trial in Cancer presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com